- Home
- VXRT vs CHRS Comparison
VXRT vs CHRS Comparison
Compare VXRT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VXRT
- CHRS
- Stock Information
- Founded
- VXRT N/A
- CHRS 2010
- Country
- VXRT United States
- CHRS United States
- Employees
- VXRT N/A
- CHRS N/A
- Industry
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VXRT Health Care
- CHRS Health Care
- Exchange
- VXRT Nasdaq
- CHRS Nasdaq
- Market Cap
- VXRT 200.3M
- CHRS 191.3M
- IPO Year
- VXRT N/A
- CHRS 2014
- Fundamental
- Price
- VXRT $0.76
- CHRS $1.32
- Analyst Decision
- VXRT Strong Buy
- CHRS Strong Buy
- Analyst Count
- VXRT 2
- CHRS 4
- Target Price
- VXRT $3.00
- CHRS $5.38
- AVG Volume (30 Days)
- VXRT 2.6M
- CHRS 2.0M
- Earning Date
- VXRT 03-13-2025
- CHRS 03-12-2025
- Dividend Yield
- VXRT N/A
- CHRS N/A
- EPS Growth
- VXRT N/A
- CHRS N/A
- EPS
- VXRT N/A
- CHRS N/A
- Revenue
- VXRT $16,760,000.00
- CHRS $304,340,000.00
- Revenue This Year
- VXRT $128.77
- CHRS $2.47
- Revenue Next Year
- VXRT N/A
- CHRS N/A
- P/E Ratio
- VXRT N/A
- CHRS N/A
- Revenue Growth
- VXRT 303.27
- CHRS 44.19
- 52 Week Low
- VXRT $0.52
- CHRS $0.66
- 52 Week High
- VXRT $1.54
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- VXRT 55.26
- CHRS 41.91
- Support Level
- VXRT $0.70
- CHRS $1.38
- Resistance Level
- VXRT $0.83
- CHRS $1.60
- Average True Range (ATR)
- VXRT 0.09
- CHRS 0.12
- MACD
- VXRT -0.00
- CHRS -0.03
- Stochastic Oscillator
- VXRT 36.62
- CHRS 1.10
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.